Cerulean Pharma Inc.'s board is conducting a comprehensive review of strategic options to maximize shareholder value.

The review is to evaluate potential alternatives such as the sale of the company; a merger; a business combination; a strategic investment in the company; or a sale, license or disposition of its assets.

Also in the review, the board is considering certain clinical assets, the company's nanoparticle-drug conjugates platform and cash reserves.